All In Biotech

NDA 019627 · Fresenius Kabi USA

Diprivan

Propofol · Injection · General Anesthetic

Novel

Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Oct 2, 1989

Approved uses

5

Original approval plus efficacy supplements

Registered trials

1,886

195 Phase 3, 129 recruiting

FAERS reports

37,021

34,684 serious, 5,006 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 11, 2025.

DIPRIVAN is an intravenous general anesthetic and sedation drug indicated for: • Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age • Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age • Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients • Sedation for Adult Patients in Combination with Regional Anesthesia • Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients Limitations of Use DIPRIVAN is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations [see Pediatric Use ( 8.4 )] . Safety, effectiveness and dosing guidelines for DIPRIVAN have not been established for MAC sedation in the pediatric population; therefore, it is not recommended for this use [see Pediatric Use ( 8.4 )]. DIPRIVAN is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established [see Pediatric Use ( 8.4 )]. DIPRIVAN is an intravenous general anesthetic and sedation drug indicated for: • Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age • Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age • Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients • Sedation for Adult Patients in Combination with Regional Anesthesia • Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients Limitations of Use : DIPRIVAN is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months....

Mechanism: The mechanism of action, like all general anesthetics, is poorly understood. However, propofol is thought to produce its sedative/anesthetic effects by the positive modulation of the inhibitory function of the neurotransmitter GABA through the ligand-gated GABA A receptors.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DIPRIVAN · PROPOFOL 10MG/ML · INJECTABLE, INJECTION · Discontinued
  • DIPRIVAN · PROPOFOL 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Propofol" as an intervention, any sponsor and status, largest first.

All 1,886 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension2,992
  • drug ineffective2,858
  • anaphylactic shock2,182
  • cardiac arrest1,851
  • anaphylactic reaction1,762
  • off label use1,736
  • drug interaction1,583
  • tachycardia1,234
  • bradycardia1,212
  • acute kidney injury1,024
  • pyrexia1,024
  • rhabdomyolysis932

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004583
2005674
2006630
2007790
2008798
20091,132
2010976
20111,396
20121,186
20131,248
20141,148
20151,307
20161,622
20171,594
20182,060
20192,181
20202,738
20212,490
20222,361
20232,779
20242,477
20252,894
20261,944

Recalls

2 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Diprivan* (Propofol*) · HCPCS J2704

2024 spending

$113K

Beneficiaries

30,945

41,328 claims

Per beneficiary

$4

2024 ASP limit $0.11 per unit

View as table
YearSpending
2020$106,991
2021$144,819
2022$137,330
2023$133,488
2024$113,209

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,948 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.